Abstract
Although the antiviral activity of erythro-9-(2-hydroxy-3-nonyl)adenine, a potent adenosine deaminase inhibitor, against herpes simplex virus type 1 in cell culture was readily confirmed, the compound was found to be totally ineffective in the treatment of experimentally induced systemic herpes simplex virus type 1 infections in Swiss mice. Data was obtained, however, which clearly indicated that the antiviral potency of 9-β-D-arabinofuranosyladenine in vivo could be enhanced by the co-administration of low, nontoxic doses of erythro-9-(2-hydroxy-3-nonyl)adenine.
Original language | English (US) |
---|---|
Pages (from-to) | 598-603 |
Number of pages | 6 |
Journal | Antimicrobial Agents and Chemotherapy |
Volume | 18 |
Issue number | 4 |
State | Published - 1980 |
Externally published | Yes |
ASJC Scopus subject areas
- Pharmacology (medical)